CN104082748A - Functional food for conditioning lipid balance - Google Patents
Functional food for conditioning lipid balance Download PDFInfo
- Publication number
- CN104082748A CN104082748A CN201410355515.3A CN201410355515A CN104082748A CN 104082748 A CN104082748 A CN 104082748A CN 201410355515 A CN201410355515 A CN 201410355515A CN 104082748 A CN104082748 A CN 104082748A
- Authority
- CN
- China
- Prior art keywords
- parts
- functional food
- raw material
- blood fat
- fat balance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 51
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 13
- 150000002632 lipids Chemical class 0.000 title abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 54
- 239000002994 raw material Substances 0.000 claims abstract description 52
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 24
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 24
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims description 56
- 239000008280 blood Substances 0.000 claims description 56
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 23
- 235000020717 hawthorn extract Nutrition 0.000 claims description 23
- 229940083466 soybean lecithin Drugs 0.000 claims description 23
- 229930003231 vitamin Natural products 0.000 claims description 16
- 239000011782 vitamin Substances 0.000 claims description 16
- 229940088594 vitamin Drugs 0.000 claims description 16
- 235000013343 vitamin Nutrition 0.000 claims description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 230000000474 nursing effect Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 45
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 9
- 108090001030 Lipoproteins Proteins 0.000 abstract description 8
- 102000004895 Lipoproteins Human genes 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002503 metabolic effect Effects 0.000 abstract description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000001603 reducing effect Effects 0.000 abstract description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 235000007106 Crataegus suborbiculata Nutrition 0.000 abstract 1
- 241000073432 Crataegus suborbiculata Species 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
- 235000013202 a hawthorn Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 41
- 235000013305 food Nutrition 0.000 description 25
- 241000700159 Rattus Species 0.000 description 23
- 238000000034 method Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 150000003626 triacylglycerols Chemical class 0.000 description 11
- 238000007689 inspection Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 235000003283 Pachira macrocarpa Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 235000014364 Trapa natans Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009165 saligot Nutrition 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a functional food for conditioning the lipid balance. The functional food is prepared from the following main raw materials in parts by weight: 20-40 parts of a hawthorn fruit extract, 20-40 parts of a lotus leaf extract, 20-40 parts of soya bean lecithin dry powder and 5-10 parts of vitamin E. Tests prove that besides the respective functions, the raw materials are rich in lipid metabolic balance factors of a human body after being kneaded to form the functional food, and the functional food is capable of remarkably increasing the content of good lipoprotein (namely high-density lipoprotein) and reducing the content of bad lipoprotein (namely low-density lipoprotein), lowering cholesterol and triglyceride, metabolizing excessive fat in the human body, and maintaining the lipid metabolic balance without toxic and side effects.
Description
Technical field
The present invention relates to field of functional food, particularly a kind of functional food of nursing one's health blood fat balance.
Background technology
Hyperlipemia is a kind of systemic disease, refers to that T-CHOL in blood (TC) and/or triglycerides (TG) are too high or HDL-C (HDL-C) is too low, and modern medicine is referred to as dyslipidemia.This disease to the infringement of health be concealment, gradually, carrying out property and general, its direct infringement is to accelerate systemic atherosclerosis, because the vitals of whole body all will rely on artery blood supply, oxygen supply, once artery is stopped up by atheromatous plaque, will cause serious consequence.Research shows, hyperlipemia is the independent and important hazards of cerebral apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death.A large amount of medical researches show: it is closely-related with dietary factor that primary hyperlipemic patients has sizable ratio, and the methods for the treatment of of high fat of blood can not, only by drug-layer side, also will be careful taking good care of of diet.
Functional food refer to there is trophic function, the food of sensory function and adjusting physiological activity function, comprising: the food that strengthens human body constitution (strengthen immunocompetence, activate lymphatic system etc.); Prevent the food of disease (hypertension, diabetes, coronary heart disease, constipation and tumour etc.); The get well food of (control cholesterol, prevent platelet aggregation, regulate hematopoiesis function etc.); Regulate the food of the health rhythm and pace of moving things (nerve center, nerve ending, picked-up and absorption function etc.) and the food delaying senility.The research and development of functional food still belong to new branch of science and field in China, are products multidisciplinary, multi-field continuous mixing together, relate to nutrition, pharmacy, physiology, preventive medicine, bioengineering, Food Science.
Therefore, it is very urgent that the functional food of blood fat is nursed one's health in development safely and effectively, is not only to reduce blood fat itself, is also the M & M of overall reduction cardiovascular disease.
Summary of the invention
The present invention is intended to solve one of technical problem in prior art problem, for this reason, the invention provides a kind of functional food of nursing one's health blood fat balance, the lipoprotein that it can obviously raise---HDL, reduce bad lipoprotein---low-density lipoprotein, reduce cholesterol and triglyceride, the superabundant fats metabolism in human body is gone out, maintain fat metabolic balance.
In one aspect of the invention, the invention provides a kind of composition, mainly made by the raw material of following parts by weight: haw thorn extract 20-40 part, Lotus Leafextract 20-40 part, soybean lecithin dry powder 20-40 part, vitamin E 5-10 part.
In addition, composition according to the above embodiment of the present invention can also have following additional technical characterictic:
In an embodiment of the present invention, composition of the present invention further comprises that the mixed raw material of following parts by weight becomes: 35 parts of haw thorn extracts, 35 parts of Lotus Leafextracts, 20 parts, soybean lecithin dry powder, 0 part of vitamin e1.
In an embodiment of the present invention, composition of the present invention further comprises that the mixed raw material of following parts by weight becomes: 30 parts of haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, 0 part of vitamin e1.
In an embodiment of the present invention, composition of the present invention further comprises that the mixed raw material of following parts by weight becomes: 35 parts of haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, 5 parts of vitamin Es.
In embodiments of the invention, also provide a kind of preparation method of functional food, according to embodiments of the invention, its preparation method is as follows:
A. the powder raw material being up to the standards and configure by proportioning is dropped in mixer, make it to stir, and to control raw material water content be 10%～20%, the weight proportion umber of these raw materials is successively: haw thorn extract 20-40 part, Lotus Leafextract 20-40 part, soybean lecithin dry powder 20-40 part, vitamin E 5-10 part.
B. the powder raw material stirring is put into microwave dryer, dry and sterilizing;
C. the powder raw material of drying after also sterilizing is pulverized, sieved, obtain fine powder;
D. described fine powder moulding is made to functional food.
According to some embodiments of the present invention, in above-mentioned preparation method, the moisture of described powder raw material is 10%-20%.
According to some embodiments of the present invention, in above-mentioned preparation method, it is 2-2.5cm that powder raw material described in described b step is put into the thickness of microwave dryer.
According to some embodiments of the present invention, in above-mentioned preparation method, powder raw material described in described b step is dried and sterilising temp is 60-80 DEG C, and the time is 4-10 minute.
According to some embodiments of the present invention, in above-mentioned preparation method, powder raw material described in described b step is dried rear moisture and is less than 7%.
According to some embodiments of the present invention, in above-mentioned preparation method, described in described c step, the powder raw material of drying after also sterilizing is pulverized to rear mistake 100 mesh sieves.
According to some embodiments of the present invention, the functional food in the present invention is at least one form of capsule, tablet or electuary.
According to embodiments of the invention, pharmaceutical composition of the present invention can be for conditioning diabetes patient's blood fat.
According to concrete examples more of the present invention, functional food to conditioning blood fat balance of the present invention has carried out functional experiment, find that a kind of functional food of nursing one's health blood fat balance provided by the invention has the effect of good step-down and adjusting blood pressure to high blood lipid model rat, long-term taking can reach the object of controlling treatment, meanwhile, the present invention has also carried out Oral toxicity test to a kind of functional food of nursing one's health blood fat provided by the invention, the safety evaluatio experiment of binomial mutagenicity test (PCEMNR is counted micronucleus test and sperm malformation test) and 30 days feeding trials and pathologic diagnosis gross anatomy test, test data does not all find that this given the test agent has obvious toxic action, press acute toxicity grading criteria evaluation, this given the test agent belongs to nontoxic level.
In the present invention, above-mentioned several raw material is except effect separately, blend into one and form after this food at it, through evidence, be rich in human body blood lipid metabolism balance factor, the lipoprotein that can obviously raise---HDL, reduce bad lipoprotein---low-density lipoprotein, reduce cholesterol and triglyceride, the superabundant fats metabolism in human body is gone out, maintain fat metabolic balance, and totally nontoxic side effect.Therefore, this food has the function of good conditioning blood fat balance, can make user regulate blood fat, reduces patient's using and relying on, the toxic and side effect that minimizing medicine brings to health lipid lowerers.On safety regulation and control blood fat, this food is that current safety effectively can be by the lipoprotein that regulates blood lipid metabolism, raise---HDL, reduce bad lipoprotein---low-density lipoprotein, reduction cholesterol and triglyceride, the superabundant fats metabolism in human body is gone out etc. and to be nursed one's health the healthy and safe property food of blood fat balance.
It should be noted that, medical composition and its use of the present invention is that present inventor just completes through arduous creative work and Optimization Work.
Additional aspect of the present invention and advantage in the following description part provide, and part will become obviously from the following description, or recognize by practice of the present invention.
Detailed description of the invention
Describe embodiments of the invention below in detail.Embodiment described below is exemplary, only for explaining the present invention, and can not be interpreted as limitation of the present invention,
A kind of functional food of nursing one's health blood fat balance provided by the invention, comprises that the mixed raw material of following parts by weight becomes:
Haw thorn extract 20-40 part, Lotus Leafextract 20-40 part, soybean lecithin dry powder 20-40 part, 5～10 parts of vitamin Es, these four kinds of raw materials are all bought from Jia Kang source, Beijing Chemical Co., Ltd..
Embodiment 1:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 35 parts of haw thorn extracts, 35 parts of Lotus Leafextracts, 20 parts, soybean lecithin dry powder, 0 part of vitamin e1.
Embodiment 2:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 30 parts of haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, 0 part of vitamin e1.
Embodiment 3:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 35 parts of haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, 5 parts of vitamin Es.
Embodiment 4:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 20 parts of haw thorn extracts, 40 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, 0 part of vitamin e1.
Embodiment 5:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 30 parts of haw thorn extracts, 20 parts of Lotus Leafextracts, 40 parts, soybean lecithin dry powder, 0 part of vitamin e1.
Embodiment 6:
A kind of composition is provided, comprises that the mixed raw material of following parts by weight becomes: 40 parts of haw thorn extracts, 20 parts of Lotus Leafextracts, 35 parts, soybean lecithin dry powder, 5 parts of vitamin Es.
Preparation method: the preparation method who the invention provides a kind of food comprises stirring, oven dry and sterilizing, pulverizing and forming step, specific as follows:
Embodiment 7:
First will meet standard (quality standard in Q/WHF 0019S-2012, as follows) 35 parts of haw thorn extracts, 35 parts of Lotus Leafextracts, 20 parts, soybean lecithin dry powder, 0 part of powder raw material of vitamin e1 (parts by weight) drops in mixer, make it to stir, and to control raw material water content be 10～20%; The raw material mixing is laid in microwave dryer by the even thickness of 2～2.5cm again, under 60～80 DEG C of temperature, 4～10 minutes time condition, carries out sterilizing and oven dry, after drying, moisture is less than 7%; Then, by dry and sterilizing after powder raw material pulverize, sieve, while sieving, can use 100 orders, 80 orders or 60 mesh sieves, wherein preferred 100 mesh sieves, obtain fine powder; Finally, require fine powder raw material to make capsule according to functions of the state food technology, or tablet, or electuary, or other kind of packaging product.
Embodiment 8: first by 30 parts of standard compliant powder raw material (parts by weight) haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, in 0 part of input mixer of vitamin e1, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 7.
Embodiment 9: first by 35 parts of standard compliant powder raw material (parts by weight) haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, in 5 parts of input mixers of vitamin E, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 7.
Embodiment 10: first by 20 parts of standard compliant powder raw material (parts by weight) haw thorn extracts, 40 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, in 0 part of input mixer of vitamin e1, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 7.
Embodiment 11: first by 30 parts of standard compliant powder raw material (parts by weight) haw thorn extracts, 20 parts of Lotus Leafextracts, 40 parts, soybean lecithin dry powder, in 0 part of input mixer of vitamin e1, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 7.
Embodiment 12: first by 40 parts of standard compliant powder raw material (parts by weight) haw thorn extracts, 20 parts of Lotus Leafextracts, 35 parts, soybean lecithin dry powder, in 5 parts of input mixers of vitamin E, make it to stir, and to control raw material water content be 10～20%; Following operation is with embodiment 7.
Functional experiment test:
Embodiment 13: the experiment test of effect of a kind of functional food provided by the invention
1. materials and methods
1.1 material
Sample: regulate blood fat function food by the one that in the above embodiment of the present invention 1 to 4, any one provides, provided by Kai Ze (Wuhan) health control Co., Ltd, human body recommended amounts is 20mg/ (dkg).
Experiment reagent: cholesterol, bovine bile: be analysis pure, derive from Chinese Medicine Solution on Chemical Reagents in Shanghai company product; Cholesterol (TC) kit, triglycerides (TG) kit, HDL-C (HDL-C) kit: Shanghai Ke Hua-Dong water chestnut diagnostic article Co., Ltd provides;
Animal used as test:
Male SD rat: 60, body weight 150～200g, is provided by Hubei Province's Experimental Animal Center, clean level.20 DEG C～24 DEG C of environment temperatures, relative humidity 40%～70%, day alternates with night 12h/12h.
Laboratory apparatus:
SPACE automatic clinical chemistry analyzer: the U.S.;
Low speed desk centrifuge: Beijing medical equipment factory.
1.2 experimental technique
Detect with assessment technique specification rat and conform after 3d by Ministry of Public Health's function of health food, feed and raise basal feed 5d, overnight fasting is adopted tail blood, centrifugal (3000rpm), get serum, survey serum TC, TG, HDL-C, be divided at random 5 groups according to TC level, be i.e. three dosage groups (0.10,0.20 and 1.00g/kg), a high lipid food control group and a basal feed control group.Experimental period,, interior three dosage groups gave the tested material of high lipid food and various dose, and high lipid food control group gives high lipid food and distilled water, and basal feed control group gives basal feed and distilled water.30d in test weighs, and gets tail blood after fasting 16h, surveys serum TC, TG, HDL-C.
1.3 data statistics processing methods
Adopt SPSS10.0 statistical software to carry out variance analysis, significance level is decided to be α=0.05
2 experimental results
2.1 a kind of functional foods that regulate blood fat balance provided by the invention on the impact of Serum TC in table 1.Result demonstration, high lipid food control animals serum TC and basal feed control group comparing difference have statistical significance (P<0.01), illustrate that this test hyperlipidemia model is successfully established.After test 0.20, a kind of functional food that regulates blood fat balance of 1.00g/kg dosage group can make TC in rat blood serum reduce, and has statistical significance (P<0.01) with high lipid food control group comparing difference.
One kind, table 1 regulates the functional food of blood fat balance to affect Serum TC
Note: each dosage group and hyperlipidemia model control group be P<0.05 relatively, P<0.01
2.2 impacts of a kind of functional food that regulates blood fat provided by the invention on rat blood serum TG, result represents after test 0.10,0.20, a kind of functional food that regulates blood fat balance of 1.00g/kg dosage group can make TG in rat blood serum reduce, there is statistical significance (P<0.05 with high lipid food control group comparing difference, P<0.01), illustrate that a kind of functional food that regulates blood fat balance has reducing effect to the TG in rat blood serum.
The impact of the functional food that one kind, table 2 regulates blood fat balance on rat blood serum TG
Note: each dosage group and hyperlipidemia model control group comparison [3] P<0.05, [33] P<0.01
3. functional experiment result
In conjunction with above each experimental data, inventor draws to draw a conclusion, a kind of functional food 0.20,1.00g/kg dosage group that regulates blood fat balance can make TC in rat blood serum obviously reduce, 0.10,0.20 and 1.00g/kg dosage group all can make in rat blood serum TG reduce.
Safety assessment test
The present invention also provides a kind of assessment experiment, pass through acute toxicity test in mice, PCEMNR is counted micronucleus test, mouse sperm deformity test, 30 days feeding trials and the test of hematological examination result and animal pathologic diagnosis are evaluated the security performance of a kind of functional food provided by the invention.
Embodiment 14:
Acute toxicity test in mice
Test method:
To the SPF level Kunming mouse acute oral toxicity test of two kinds of sexes, method is by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, twice gavage 20g/kg BW (be equivalent to crowd's recommended intake 0.02g/kg BW 1000 times), within the observation period of 14 days, mouse test the results are shown in Table 3.
One kind, table 3 regulates the functional food of blood fat balance to acute toxicity test in mice result
Test data shows, two treated animals are not all observed Novel presentation, has no animal poisoning symptom and dead generation in two weeks.Press acute toxicity grading criteria evaluation, this given the test agent belongs to nontoxic level.
Embodiment 15:
Binomial mutagenicity test
PCEMNR is counted micronucleus test
Test method:
SPF level Kunming mouse marrow polychromatic erythrocyte to two kinds of sexes is counted micronucleus test, and method, by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, the results are shown in Table 4.
One kind, table 4 regulates the functional food of blood fat balance to count micronucleus test result to PCEMNR
Note: with relatively * * P < 0.01 of negative control group
With negative control group comparison, positive controls male and female micronuclei in mice rate there were significant differences property (< 0.01), and the each dosage group of given the test agent male and female micronuclei in mice rate and negative control group comparison, difference that there are no significant (P > 0.05), and all, in normal range (NR), show that this given the test agent bone marrow micronucleus test result is negative.Mouse sperm deformity test
Test method:
To the sperm malformation test of SPF level Kunming mouse, method, by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, the results are shown in Table 5.
One kind, table 5 regulates the functional food of blood fat balance to mouse sperm deformity result of the test
Note: with relatively * * P < 0.01 of negative control group
Result of the test shows, with negative control group comparison, positive controls mouse sperm deformity rate has significant difference (P < 0.01), and the each dosage group of given the test agent mouse sperm deformity rate and negative control group comparison, difference that there are no significant (P > 0.05), shows that this given the test agent sperm malformation test result is negative.
Embodiment 16:
30 days feeding trials
Test method:
To 30 days feeding trials of SPF level Wistar rat of two kinds of sexes, method, by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, the results are shown in Table 6-8 to the impact of rat body weight, food-intake, food utilization.
One kind, table 6 regulates the functional food of blood fat balance on the impact of rat body weight (mean ± standard deviation)
The impact (mean ± standard deviation) of the functional food that one kind, table 7 regulates blood fat balance on rats eating amount
The impact (mean ± standard deviation) of the functional food that one kind, table 8 regulates blood fat balance on rat food utilization
Result of the test shows, in process of the test, animal is without death, and hair is normal, shows without abnormal behaviour.There are no significant (P > 0.05) to rat body weight, food-intake, food utilization and negative control group comparing difference for the each dosage group of given the test agent.
Embodiment 17:
The test of hematological examination result
On the impact of rat serum routine inspection, on the impact of rat leukocyte classification, rat blood biochemical analysis affected to result respectively in Table 9-11.
The impact (mean ± standard deviation) of the functional food that one kind, table 9 regulates blood fat balance on rat serum routine inspection result
Table 10 impact (mean ± standard deviation) that regulates the functional food of blood fat balance to classify on rat leukocyte
The impact (mean ± standard deviation) of the functional food that one kind, table 11 regulates blood fat balance on rat blood biochemical analysis
continued
Result of the test as seen from Table 9, the each dosage group of given the test agent and negative control group comparison, difference that there are no significant (P > 0.05), and all in range of normal value.As seen from Table 10, the each dosage group of given the test agent and negative control group comparison, difference that there are no significant (P > 0.05), and all in range of normal value.From table 11, measurement result and the negative control group comparison of the each dosage group of given the test agent rat blood serum ALT, AST, BUN, CRE, GLU, TRI, CHO, ALB, TP, difference that there are no significant (P > 0.05), and all in range of normal value.
Embodiment 18:
Pathologic diagnosis gross anatomy:
The heart of the female male rat of each test dose group, liver,spleen,kidney, stomach and intestine and Normal group relatively its appearance color and Organ size normal, be showed no obviously ooze out, the pathology such as hyperplasia, oedema, atrophy.Finding under mirror:
High dose group and normal group comparison: result is all in normal morphology scope, having no obvious Poisoning pathology changes, wherein: liver: lobuli hepatis structure is normal, liver cell is radioactivity and arranges, the visible slight cloudy swelling of minority liver cell section (Normal group 4 example and high dose group 2 examples), sinus hepaticus has no obvious inflammatory cell and invades profit, and the portal area accidental inflammatory cell of minority animal is invaded profit, (control group 3 example and high dose group 2 examples), non-experiment is with due to sample toxicity.Kidney: the visible glomerulus of cortex renis part and near, distal vessels, even dyeing; Have no obvious pathological change.Stomach and intestine: under mucous membrane, mucous membrane, flesh layer, placenta percreta be showed no inflammatory cell and invade profit and hemorrhagic focus, sticky touch complete.Spleen: control group spleen extravasated blood 2 examples, slight inflammatory cell is invaded profit 2 examples, high dose group spleen extravasated blood and slight inflammatory cell are invaded each 1 example of profit, more than have no other abnormal pathological change.In conjunction with above each experimental data, inventor draws to draw a conclusion, and a kind of functional food that regulates blood fat balance provided by the invention is a kind of food of safety non-toxic, can play the effect that regulates blood fat, is again safety non-toxic to high fat of blood patient.
Although illustrated and described embodiments of the invention, those having ordinary skill in the art will appreciate that, in the situation that not departing from principle of the present invention and aim, can carry out multiple variation, amendment, replacement and modification to these embodiment, scope of the present invention is limited by claim and equivalent thereof.
Claims (10)
1. a functional food of nursing one's health blood fat balance, is characterized in that, comprises haw thorn extract, Lotus Leafextract, soybean lecithin dry powder, vitamin E.
2. according to the functional food of the conditioning blood fat balance described in claims 1, it is characterized in that, comprise that the mixed raw material of following parts by weight becomes: haw thorn extract 20-40 part, Lotus Leafextract 20-40 part, soybean lecithin dry powder 20-40 part, vitamin E 5-10 part.
3. the functional food of conditioning blood fat balance according to claim 1, is characterized in that, comprises that the mixed raw material of following parts by weight becomes: 35 parts of haw thorn extracts, 35 parts of Lotus Leafextracts, 20 parts, soybean lecithin dry powder, 0 part of vitamin e1.
4. the functional food of conditioning blood fat balance according to claim 1, is characterized in that, comprises that the mixed raw material of following parts by weight becomes: 30 parts of haw thorn extracts, 30 parts of Lotus Leafextracts, 30 parts, soybean lecithin dry powder, 0 part of vitamin e1.
5. according to the functional food of the arbitrary described conditioning blood fat balance of claim 1 to 4, it is characterized in that, described functional food is at least one form of capsule, tablet or electuary.
6. a preparation method who nurses one's health the functional food of blood fat balance, is characterized in that, prepares through the following steps:
A. the powder raw material being up to the standards and configure by proportioning is dropped in mixer, make it to stir, and to control described powder raw material water content be 10%～20%, the weight proportion umber of these powder raw materials is successively: haw thorn extract 20-40 part, Lotus Leafextract 20-40 part, soybean lecithin dry powder 20-40 part, vitamin E 5-10 part.
B. the powder raw material stirring is put into microwave dryer, dry and sterilizing;
C. the powder raw material of drying after also sterilizing is pulverized, sieved, obtain fine powder;
D. described fine powder moulding is made to functional food.
7. the preparation method of the functional food of conditioning blood fat balance according to claim 6, is characterized in that, it is 2-2.5cm that powder raw material described in described b step is put into the thickness of microwave dryer.
8. the preparation method of the functional food of conditioning blood fat balance according to claim 6, is characterized in that, powder raw material described in described b step is dried and sterilising temp is 60-80 DEG C, and the time is 4-10 minute.
9. the preparation method of the functional food of conditioning blood fat balance according to claim 6, is characterized in that, powder raw material described in described b step is dried rear moisture and is less than 7%.
10. the preparation method of the functional food of conditioning blood fat balance according to claim 6, is characterized in that, in described c step, the powder raw material of drying after also sterilizing is pulverized to rear mistake 100 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410355515.3A CN104082748A (en) | 2014-07-23 | 2014-07-23 | Functional food for conditioning lipid balance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410355515.3A CN104082748A (en) | 2014-07-23 | 2014-07-23 | Functional food for conditioning lipid balance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104082748A true CN104082748A (en) | 2014-10-08 |
Family
ID=51630596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410355515.3A Pending CN104082748A (en) | 2014-07-23 | 2014-07-23 | Functional food for conditioning lipid balance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104082748A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045189A (en) * | 2018-11-01 | 2018-12-21 | 苏州卫生职业技术学院 | A kind of Chinese medicine composition and preparation method thereof with adjusting blood fat function |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030036480A (en) * | 2000-02-03 | 2003-05-09 | (주)케이비피 | Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same |
| CN1554408A (en) * | 2003-12-23 | 2004-12-15 | 天津中新药业集团股份有限公司达仁堂 | Medicine for lowering blood lipid and softening blood vessel and its preparing method |
| CN1792247A (en) * | 2005-12-27 | 2006-06-28 | 武汉哈福科技有限公司 | Health-care food with functions of anti-senium and cosmetic |
| CN1899052A (en) * | 2006-07-08 | 2007-01-24 | 南昌大学 | Method for preparing milk powder for regulating blood fat |
| CN101695377A (en) * | 2009-09-14 | 2010-04-21 | 蔡晓东 | Soya bean lecithin soft capsule |
-
2014
- 2014-07-23 CN CN201410355515.3A patent/CN104082748A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030036480A (en) * | 2000-02-03 | 2003-05-09 | (주)케이비피 | Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same |
| CN1554408A (en) * | 2003-12-23 | 2004-12-15 | 天津中新药业集团股份有限公司达仁堂 | Medicine for lowering blood lipid and softening blood vessel and its preparing method |
| CN1792247A (en) * | 2005-12-27 | 2006-06-28 | 武汉哈福科技有限公司 | Health-care food with functions of anti-senium and cosmetic |
| CN1899052A (en) * | 2006-07-08 | 2007-01-24 | 南昌大学 | Method for preparing milk powder for regulating blood fat |
| CN101695377A (en) * | 2009-09-14 | 2010-04-21 | 蔡晓东 | Soya bean lecithin soft capsule |
Non-Patent Citations (3)
| Title |
|---|
| 吕连凤，等: "《不用药物降血脂》", 31 July 2012, 河北科学技术出版社 * |
| 杨玺: "《血脂异常饮食调控》", 31 May 2009, 科学技术文献出版社 * |
| 马汴梁: "《排毒养颜茶酒方》", 28 February 2014, 金盾出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045189A (en) * | 2018-11-01 | 2018-12-21 | 苏州卫生职业技术学院 | A kind of Chinese medicine composition and preparation method thereof with adjusting blood fat function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN102697060B (en) | Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof | |
| CN102940733B (en) | Composition for relieving physical fatigue and preparation method and application thereof | |
| CN102172269B (en) | Hidegelatin fabricated food with beautification function | |
| CN102215850B (en) | Composition containing fucoxanthin extract | |
| CN104095234B (en) | A kind of functional food nursing one's health fatty liver | |
| CN102919851B (en) | Health-care food composition for assisting to improve memory and preparation method thereof | |
| Babich et al. | In vivo study of the potential of the carbohydrate-mineral complex from pine nut shells as an ingredient of functional food products | |
| CN102178217B (en) | Konjac-flour-containing mixture and preparation method thereof | |
| CN104938684A (en) | Tea for assisting reduction of blood lipid and preparation method thereof | |
| CN103190511A (en) | Ginseng coffee | |
| CN109602023A (en) | A kind of functional food and preparation method thereof assisting reducing blood lipid using soybean as primary raw material | |
| CN103735556B (en) | A kind of multi-vitamin mineral composite effervescent sheet and preparation method | |
| CN106376934A (en) | Ketogenic-diet composition containing active polysaccharide, and preparation and application methods thereof | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN103784939A (en) | Composition for enhancing bone mineral density | |
| CN105725187B (en) | A kind of hypoglycemic composition and its purposes for being used to prepare food and health food | |
| CN106063795B (en) | The application of forsythin, its derivative, forsythin and phillygenol composition in preparation prevention or/and treatment hyperlipemia drug | |
| CN104171799A (en) | Phospholipid-phytosterol composite nutrition product capable of reducing blood fat and preparation method thereof | |
| CN103127395B (en) | Dendrobe anti-oxidation preparation and preparation method thereof | |
| CN104082748A (en) | Functional food for conditioning lipid balance | |
| CN104523815A (en) | Soft capsules and production method thereof | |
| CN105410941A (en) | Serene Tablet health-care food capable of increasing bone density and strengthening immunity and preparation method thereof | |
| CN105558244A (en) | Food assisting in reducing blood lipid, reducing blood sugar and improving immunity and preparation method of food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141008 |